证券代码：600196 证券简称：复星医药 公告编号：临 2026-021 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 名称 | 复星健康 | | --- | --- | --- | | | 本次担保金额 | 人民币 2,000 万元 | | 被担保方 1 | 截至 2026 年 2 月 11 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 折合人民币约 215,268 万元 | | | 是否在前期预计额度内 | 是 □否 □不适用：________ | | | 本次担保是否有反担保 | □否 □不适用：________ 是 | | | 名称 本次担保金额 | 复星诊断长沙 人民币 2,500 万元 | | 被担保方 2 | 截至 2026 年 2 月 11 日， 包括本次担保在内，本集 团实际为其提供的担保 余额 | 人民币 14,918 万元 | | | 是否在前期预计额度内 | 是 □ ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公司上海朝晖药业有限公司就 盐酸丁卡因凝胶（以下简称"该药品"）的药品注册申请获国家药品监督管理局受理。 证券代码：600196 股票简称：复星医药 编号：临2026-020 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获 受理的公告 三、对上市公司的影响及风险提示 该药品在进行商业化生产前，尚需（其中主要包括）通过GMP符合性检查、获得药品注册批准等。本 次药品注册申请获受理不会对本集团现阶段业绩产生重大影响。 由于医药产品的行业特点，药品上市后的具体销售情况可能受到（包括但不限于）用药需求、市场竞 争、销售渠道等因素影响，具有较大不确定性。敬请广大投资者注意投资风险。 特此公告。 上海复星医药（集团）股份有限公司 董事会 二零二六年二月十日 二、该药品的基本信息及研究情况 该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的化学药品；拟用于经皮局部麻醉， 在静脉穿刺或静脉插管前 ...

格隆汇2月10日丨复星医药(02196.HK)发布公告，近日，公司控股子公司上海朝晖药业有限公司就盐酸 丁卡因凝胶的药品注册申请获国家药品监督管理局受理。该药品为集团(即公司及控股子公司/单位，下 同)自主研发的化学药品；拟用于经皮局部麻醉，在静脉穿刺或静脉插管前对皮肤进行麻醉，适用于成 人及 1个月以上的婴儿。 复星医药(02196.HK)：盐酸丁卡因凝胶药品注册申请获受理 复星医药(600196.SH)：控股子公司药品注 册申请获受理 相关事件 ...

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

该药品为集团自主研发的化学药品;拟用于经皮局部麻醉，在静脉穿刺或静脉插管前对皮肤进行麻醉， 适用于成人及1个月以上的婴儿。截至2025年12月，集团现阶段针对该药品的累计研发投入约为人民币 719万元(未经审计)。根据IQVIA CHPA 最新数据，2024年，盐酸丁卡因凝胶剂于中国境内(不包括港澳 台地区)的销售额约为人民币4.43亿元。 智通财经APP讯，复星医药(02196)发布公告，近日，公司控股子公司上海朝晖药业有限公司就盐酸丁卡 因凝胶的药品注册申请获国家药品监督管理局受理。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品註冊申請獲受理的公告》，僅供參閱。 承董事會命 中國，上海 2026 年2 月1 0 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 证 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-020 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海朝晖药业有限公司就盐酸丁卡因凝胶（以下简称"该药品"）的药品注册申 请获国家药品监督管理局受理。 二、该药品的基本信息及研究情况 三、对上市公司的影响及风险提示 该药品在进行商业化生产前，尚需（其中主要包括）通过 GMP 符合性检查、获 得药品注册批准等。本次药品注册申请获受理不会对本集团现阶段业绩产生重大影 响。 1 由 IQVIA 提供，IQVIA 是全球医药健康产业专业信息和战略咨询服务提供商；IQVIA CHPA 数据代表中国境 内 100 张床位以上的医院药品销售市场，不同的药品因其各自销售渠道布局的不同，实际销售情况可能与 IQVIA CHPA 数据存在不同程度的差异。 1 由于医药产品的行业特点，药品上市后的具体销售情况可能受到（包括但不 ...

复星医药公告称，其控股子公司上海朝晖药业的盐酸丁卡因凝胶药品注册申请获国家药监局受理。该药 品为集团自主研发的化学药，拟用于经皮局部麻醉。截至2025年12月，集团针对该药品累计研发投入约 719万元。2024年，该药品中国境内销售额约4.43亿元。药品商业化生产前需多项审批，本次受理暂不 影响现阶段业绩，销售情况具不确定性。 ...

医药赛道方面，2025年多项关键性的创新药BD为未来复星创新药的可持续性增长，打下了坚实的基 础。其中，复星医药控股子公司药友制药与辉瑞签订全球独家许可协议，授予辉瑞口服小分子GLP-1药 物YP05002全球范围内独家开发、生产及商业化权利，协议包含首付款、里程碑付款及销售分层特许权 使用费，潜在总金额超20亿美元；复星医药控股子公司复星医药产业与生物技术公司Clavis Bio达成战 略合作，双方将基于由Clavis Bio提名的前沿靶点共同开发创新疗法，根据协议，复星医药将可获得至 多72.5亿美元付款。 2026年开年以来，复星在旅文、医药、保险等核心赛道表现亮眼。公开信息显示，复星旗下ClubMed国 内5家精致"一价全包"度假村入境营业额较去年同期实现翻三倍增长，旗下生物医药研发平台复宏汉霖 宣布与卫材株式会社就抗PD-1单抗汉斯状在日本达成独家商业化及共同独家开发与生产许可协议，潜 在总金额超3亿美元。 新春旅游需求的承接及创新药的持续商业化落地等，延续了复星2025年核心赛道稳中有升的发展态势。 纵观复星过去一年的发展和今年的开年势头，"瘦身健体"的战略推进依旧坚定：退出一些非核心项目的 同时 ...

Core Insights - Fosun has reported significant growth in its core sectors, including tourism, pharmaceuticals, and insurance, with notable achievements in early 2026 [1][2][3] Tourism Sector Performance - Fosun's Club Med resorts in China saw a threefold increase in inbound revenue compared to the same period last year, with a 33% revenue growth during the New Year period [1][2] - The company launched three major product lines in 2025, resulting in 14 project signings, including five super resorts and eight super tourism zones [2] - The average occupancy rate for three ice and snow resorts exceeded 97%, while two sunshine resorts doubled their revenue [2] Pharmaceutical Sector Developments - Fosun Pharma's subsidiary signed a global exclusive licensing agreement with Pfizer for a GLP-1 drug, with potential total payments exceeding $2 billion [3] - The company is also collaborating with Clavis Bio for innovative therapies, with potential payments up to $7.25 billion [3] - Fosun's innovative drugs are expected to achieve significant market breakthroughs in 2026, with several products anticipated to receive regulatory approvals [3] Insurance Sector Growth - Fosun's insurance companies reported substantial growth, with Fosun United Health Insurance's revenue reaching 7.84 billion yuan, a 50% increase year-on-year [3][4] - Fosun Baodexin Life Insurance achieved a 36.2% revenue growth, totaling 12.6 billion yuan, with a net profit increase of over 450% [3][4] Financial Health and Strategy - Fosun has maintained a strong financial position, with a debt-to-capital ratio of 53% and a decrease in debt costs [5][6] - The company successfully executed significant equity sales, raising substantial funds to support its core business focus [6] - Fosun plans to reduce interest-bearing debt by approximately 10 billion yuan annually over the next two to three years, aiming for an "investment-grade" rating [6] Future Prospects - Fosun is preparing for potential IPOs of two subsidiaries, which could enhance strategic synergies and investment returns [7] - The company is well-positioned to capitalize on opportunities in the aging population and the growing demand for health and wellness, as well as tourism in emerging markets [7][8]